Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)

Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)

User Photo
BeaconMedIC

2 years
369 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients with chemo-naïve advanced non-squamous NSCLC.
Up Next Autoplay
User Photo